Search Results - "Gettinger SN"

Management of patients with advanced non-small cell lung cancer.

Authors: Triano LR Deshpande H Gettinger SN

Source: Drugs. 2010, Vol. 70 Issue 2, p167-179.

URL: 48132525

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors: Topalian SL Hodi FS Brahmer JR et al.

Source: New England Journal of Medicine. 6/28/2012, Vol. 366 Issue 26, p2443-2454. 12p.

Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors.

Authors: Schoenfeld AJ Lee SM Doger de Spéville B et al.

Source: Cancer discovery [Cancer Discov] 2024 Aug 02; Vol. 14 (8), pp. 1389-1402.

Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE

Clinical characteristics and outcomes of splenic infarction in cancer patients: a retrospective, single center report of 206 cases.

Authors: Bewersdorf JP Parmar N Israel GM et al.

Source: Journal of thrombosis and thrombolysis [J Thromb Thrombolysis] 2021 Oct; Vol. 52 (3), pp. 854-862. Date of Electronic Publication: 2021 Mar 25.

Publication Type: Journal Article

Journal Info: Publisher: Kluwer Academic Publishers Country of Publication: Netherlands NLM ID: 9502018 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-742X (Electronic) Linking ISSN: 09295305 NLM ISO Abbreviation: J Thromb Thrombolysis Subsets: MEDLINE

Phase II Trial of Afatinib in Patients With EGFR-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A.

Authors: Gettinger SN Song Z Reckamp KL et al.

Source: JCO precision oncology [JCO Precis Oncol] 2024 Jul; Vol. 8, pp. e2300725.

Publication Type: Journal Article; Clinical Trial, Phase II; Research Support, N.I.H., Extramural

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE

Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non-Small Cell Lung Cancer.

Authors: Uhlig J Case MD Blasberg JD et al.

Source: JAMA network open [JAMA Netw Open] 2019 Aug 02; Vol. 2 (8), pp. e199702. Date of Electronic Publication: 2019 Aug 02.

Publication Type: Comparative Study; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.

Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101729235 Publication Model: Electronic Cited Medium: Internet ISSN: 2574-3805 (Electronic) Linking ISSN: 25743805 NLM ISO Abbreviation: JAMA Netw Open Subsets: MEDLINE

Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I.

Authors: Unger JM Qian L Redman MW et al.

Source: Journal of the National Cancer Institute [J Natl Cancer Inst] 2023 Apr 11; Vol. 115 (4), pp. 437-446.

Publication Type: Clinical Trial, Phase III; Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

Journal Info: Publisher: Oxford University Press Country of Publication: United States NLM ID: 7503089 Publication Model: Print Cited Medium: Internet ISSN: 1460-2105 (Electronic) Linking ISSN: 00278874 NLM ISO Abbreviation: J Natl Cancer Inst Subsets: MEDLINE

Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG).

Authors: Lee SM Fan W Wang A et al.

Source: JCO clinical cancer informatics [JCO Clin Cancer Inform] 2023 Apr; Vol. 7, pp. e2200165.

Publication Type: Clinical Trial, Phase III; Randomized Controlled Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101708809 Publication Model: Print Cited Medium: Internet ISSN: 2473-4276 (Electronic) Linking ISSN: 24734276 NLM ISO Abbreviation: JCO Clin Cancer Inform Subsets: MEDLINE

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers.

Authors: Gettinger SN Choi J Mani N et al.

Source: Nature communications [Nat Commun] 2018 Aug 10; Vol. 9 (1), pp. 3196. Date of Electronic Publication: 2018 Aug 10.

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

Microwave Ablation versus Stereotactic Body Radiotherapy for Stage I Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis.

Authors: Wu X Uhlig J Blasberg JD et al.

Source: Journal of vascular and interventional radiology : JVIR [J Vasc Interv Radiol] 2022 Aug; Vol. 33 (8), pp. 964-971.e2. Date of Electronic Publication: 2022 Apr 28.

Publication Type: Journal Article

Journal Info: Publisher: Society of Cardiovascular and Interventional Radiology Country of Publication: United States NLM ID: 9203369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1535-7732 (Electronic) Linking ISSN: 10510443 NLM ISO Abbreviation: J Vasc Interv Radiol Subsets: MEDLINE

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials.

Authors: Gettinger SN Huber RM Kim DW et al.

Source: JTO clinical and research reports [JTO Clin Res Rep] 2022 Jul 31; Vol. 3 (9), pp. 100385. Date of Electronic Publication: 2022 Jul 31 (Print Publication: 2022).

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101769967 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-3643 (Electronic) Linking ISSN: 26663643 NLM ISO Abbreviation: JTO Clin Res Rep Subsets: PubMed not MEDLINE

Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC.

Authors: Kim DW Gadgeel S Gettinger SN et al.

Source: JTO clinical and research reports [JTO Clin Res Rep] 2022 Jun 25; Vol. 3 (8), pp. 100367. Date of Electronic Publication: 2022 Jun 25 (Print Publication: 2022).

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101769967 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-3643 (Electronic) Linking ISSN: 26663643 NLM ISO Abbreviation: JTO Clin Res Rep Subsets: PubMed not MEDLINE

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer.

Authors: Schoenfeld AJ Antonia SJ Awad MM et al.

Source: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Dec; Vol. 32 (12), pp. 1597-1607. Date of Electronic Publication: 2021 Sep 03.

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE

Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.

Authors: Camidge DR Kim HR Ahn MJ et al.

Source: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2021 Dec; Vol. 16 (12), pp. 2091-2108. Date of Electronic Publication: 2021 Sep 16.

Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101274235 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1556-1380 (Electronic) Linking ISSN: 15560864 NLM ISO Abbreviation: J Thorac Oncol Subsets: MEDLINE

Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.

Authors: Gettinger SN Redman MW Bazhenova L et al.

Source: JAMA oncology [JAMA Oncol] 2021 Sep 01; Vol. 7 (9), pp. 1368-1377.

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural

Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE

Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers.

Authors: Hellmann MD Sturm I Trnkova ZJ et al.

Source: Clinical lung cancer [Clin Lung Cancer] 2015 Nov; Vol. 16 (6), pp. 514-22. Date of Electronic Publication: 2015 Apr 20.

Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 100893225 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0690 (Electronic) Linking ISSN: 15257304 NLM ISO Abbreviation: Clin Lung Cancer Subsets: MEDLINE

A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811).

Authors: Argiris A Miao J Cristea MC et al.

Source: Clinical lung cancer [Clin Lung Cancer] 2021 Jul; Vol. 22 (4), pp. 313-323.e1. Date of Electronic Publication: 2021 Feb 19.

Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 100893225 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0690 (Electronic) Linking ISSN: 15257304 NLM ISO Abbreviation: Clin Lung Cancer Subsets: MEDLINE

Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo.

Authors: Foggetti G Li C Cai H et al.

Source: Cancer discovery [Cancer Discov] 2021 Jul; Vol. 11 (7), pp. 1736-1753. Date of Electronic Publication: 2021 Mar 11.

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE

Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403.

Authors: Goldberg SB Redman MW Lilenbaum R et al.

Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Dec 01; Vol. 38 (34), pp. 4076-4085. Date of Electronic Publication: 2020 Oct 06.

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.

Authors: Camidge DR Kim HR Ahn MJ et al.

Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Nov 01; Vol. 38 (31), pp. 3592-3603. Date of Electronic Publication: 2020 Aug 11.

Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE